The small Swiss biotech firm featured in today’s article has been developing a drug that could help patients suffering from severe COVID-19 – and with early-stage results showing promise, the firm’s stock has exploded 38,000% higher so far this year. Now the firm’s chairman has revealed that it has been in contact with the U.S. government’s Operation Warp Speed – and believes that if the drug proves effective in treating COVID-19 related respiratory distress, the pandemic could be just “the tip of the iceberg” for its prospects. For more, CLICK HERE.